tiprankstipranks
Amryt Pharma (DE:3N9A)
STUTTGART:3N9A
Holding DE:3N9A?
Track your performance easily

Amryt Pharma (3N9A) Income Statement

0 Followers

Amryt Pharma Income Statement

Last quarter (Q ), Amryt Pharma's total revenue was $61.13M, an increase of 8.15% from the same quarter last year. In Q, Amryt Pharma's net income was $-20.80M. See Amryt Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 243.62M$ 222.54M$ 182.61M$ 58.12M$ 17.09M$ 15.33M
Cost of Revenue
$ 127.03M$ 106.12M$ 119.03M$ 38.73M$ 6.27M$ 6.45M
Gross Profit
$ 116.59M$ 116.42M$ 63.58M$ 19.39M$ 10.83M$ 8.88M
Operating Expense
$ 161.67M$ 129.72M$ 109.02M$ 52.17M$ 28.87M$ 25.93M
Operating Income
$ -45.08M$ -13.30M$ -45.44M$ -32.77M$ -18.04M$ -17.04M
Net Non Operating Interest Income Expense
$ -27.84M$ 5.28M$ -22.27M$ -10.02M$ -1.62M$ -1.01M
Other Income Expense
$ 71.56M$ -4.42M$ -38.15M$ -22.21M$ -10.79M-
Pretax Income
$ -1.36M$ -2.14M$ -105.86M$ -63.49M$ -30.44M$ -31.36M
Tax Provision
$ -572.00K$ -7.56M$ -1.33M$ -495.00K$ 43.00K$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -790.00K$ 5.42M$ -104.53M$ -63.00M$ -30.49M$ -31.36M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
--$ 623.00K$ 170.00K$ 300.00K$ 337.12K
Total Expenses
$ 288.70M$ 235.84M$ 228.05M$ 90.90M$ 35.13M$ 32.37M
Net Income From Continuing And Discontinued Operation
$ -790.00K$ 5.42M$ -104.53M$ -63.00M$ -30.49M$ -31.36M
Normalized Income
$ -60.91M-$ -66.86M$ -38.74M$ -13.19M$ -18.03M
Interest Expense
$ 27.54M-$ 22.34M$ 9.99M$ 1.60M$ 1.01M
EBIT
$ 26.18M$ -7.42M$ -83.52M$ -53.50M$ -28.84M$ -30.34M
EBITDA
$ 72.85M$ 47.74M$ -39.06M$ -41.22M$ -28.47M$ -30.03M
Currency in USD

Amryt Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis